Description: LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. Target: S6 Kinase. Smiles: Oc1c(F)cc(cc1F)-c1cnccc1-c1ccc(cc1)N1CCOCC1. References: Aronchik I, et al. Mol Cancer Res. 2014, 12(5), 803-812.

LJI308 is a selective and potent inhibitor of the p90 ribosomal S6 kinase (RSK) family with IC50 values ranging from 4 to 13 nM for RSK isoforms 1-3. In a panel of 442 kinases, LJI308 is selective for RSK1, RSK3, and RSK4. It also inhibits S6K1, MEK4, and HIP in the low micromolar range but had no effect on other...